Efficacy of Staged Treatment Strategy for XXXX with Synchronous Double Cancers of the Esophagus and Head and Neck: A Retrospective Study.

@entity1 @entity135 @entity5 @entity1349
OBJECTIVE: To determine whether a staged treatment strategy is acceptable for @entity1 with @entity5 . BACKGROUND: Synchronous occurrence of esophageal and @entity135 is frequently observed. METHODS: We retrospectively reviewed the records of 109 @entity1 with @entity5 of the esophagus and H_N treated between 2005 and 2011. Fifty-one @entity1 underwent synchronous treatment and 58 underwent staged treatment. We measured the delay in treatment for the second @entity5 in the staged treatment group and evaluated how many @entity1 experienced progression of the second @entity5 during the first @entity5 treatment. @entity1349 ( @entity1349 ) was analyzed in 100 @entity1 who underwent potentially curative treatment. RESULTS: Synchronous treatment strategy was frequently selected for @entity1 with both advanced @entity5 (77  %) compared with those who had @entity5 in either or both organs (43  %) (P  =  0.02). The median delay in the treatment for the second @entity5 was 80  days; 77.5  days in the H_N-first group and 96  days in the esophagus-first group. Only one @entity1 experienced stage progression during the waiting period. There was no significant difference in @entity1349 between the synchronous treatment group and the staged treatment group (P  =  0.73), and no significant difference in @entity1349 among @entity1 who had @entity5 in the H_N, esophagus, or both. CONCLUSIONS: Prognosis of @entity1 with @entity5 depends on that of the more @entity5 , and waiting for treatment of @entity5 may not influence survival. The staged treatment strategy is acceptable when either of the double @entity5 is at an early stage.
